NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of “Buy” from Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) have received a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among analysts that have covered the stock in the last year is $36.20.

NAMS has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank boosted their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84. Following the completion of the sale, the insider now owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 353,542 shares of company stock valued at $8,599,328 over the last three months. Company insiders own 19.50% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC lifted its stake in NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after acquiring an additional 86,712 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after purchasing an additional 221,305 shares during the period. abrdn plc lifted its position in shares of NewAmsterdam Pharma by 69.8% in the third quarter. abrdn plc now owns 129,060 shares of the company’s stock worth $2,142,000 after purchasing an additional 53,060 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 23.0% during the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after purchasing an additional 217,902 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of NewAmsterdam Pharma by 8.9% during the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after acquiring an additional 83,115 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $25.95 on Thursday. The firm’s 50-day moving average is $21.72 and its two-hundred day moving average is $19.09. NewAmsterdam Pharma has a 52 week low of $10.50 and a 52 week high of $27.29.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.